Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shingrix + Boostrix
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Shingrix + Boostrix refers to the concurrent administration of two vaccines developed by GSK: Shingrix (Herpes Zoster Vaccine, Recombinant, Adjuvanted) and Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed). Shingrix is a non-live, recombinant subunit vaccine containing the varicella-zoster virus glycoprotein E antigen and the AS01B adjuvant system, designed to prevent herpes zoster (shingles) in adults. Boostrix is a Tdap vaccine used for active booster immunization against tetanus, diphtheria, and pertussis. Clinical trials, such as NCT02114359, have evaluated the safety and immunogenicity of co-administering these vaccines to provide comprehensive protection against these four diseases in a single visit for adults aged 50 and older.
- Other names
- Shingrix and Boostrix Co-administrationHerpes Zoster vaccine recombinant adjuvanted + Tdap vaccine
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)PRN (Pertactin)TLR4 (Toll-like receptor 4)gE (VZV glycoprotein E)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Shingrix + Boostrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shingrix + Boostrix.